Protagonist Therapeutics ... (PTGX)
NASDAQ: PTGX
· Real-Time Price · USD
53.31
-0.61 (-1.13%)
At close: Jun 20, 2025, 3:59 PM
53.34
0.06%
After-hours: Jun 20, 2025, 05:01 PM EDT
-1.13% (1D)
| Bid | 45.76 |
| Market Cap | 3.3B |
| Revenue (ttm) | 207.8M |
| Net Income (ttm) | 56.19M |
| EPS (ttm) | 0.78 |
| PE Ratio (ttm) | 68.35 |
| Forward PE | -898.67 |
| Analyst | Buy |
| Ask | 56 |
| Volume | 400,318 |
| Avg. Volume (20D) | 1,063,503 |
| Open | 54.00 |
| Previous Close | 53.92 |
| Day's Range | 52.79 - 54.49 |
| 52-Week Range | 30.67 - 60.60 |
| Beta | 2.25 |
About PTGX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PTGX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PTGX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Protagonist Therapeutics Inc. is scheduled to release its earnings on Aug 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+45.89%
Protagonist Therapeutics shares are trading higher...
Unlock content with
Pro Subscription
3 months ago
+2.42%
Protagonist Therapeutics shares are trading higher after the company announced its Polycythemia Vera Phase 3 study with Takeda met all its key goals.
1 month ago · accessnewswire.com
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate UpdatePositive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call ...
